Low Grade Glioma Market on Track for Major Expansion by 2034, According to DelveInsight | Day One Biopharma, Servier, SpringWorks Therapeutics, AnHeart Therapeutics, Beigene

DelveInsight's "Low Grade Glioma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Low Grade Glioma, historical and forecasted epidemiology as well as the Low Grade Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Low Grade Glioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Low Grade Glioma Market Forecast
https://www.delveinsight.com/sample-request/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Low Grade Glioma Market Report:
• The Low Grade Glioma market size was valued ~USD 990 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2023, the total market size for low-grade glioma in the United States was projected to exceed USD 550 million, with anticipated growth throughout the forecast period from 2024 to 2034.
• In 2022, the market size of low-grade glioma (LGG) in Japan is below USD 100 million, with an anticipated increase during the forecast period from 2024 to 2034.
• In April 2024, Day One Biopharmaceuticals revealed that OJEMDA (tovorafenib) has received FDA approval under accelerated approval for patients aged 6 months and older diagnosed with relapsed or refractory pediatric low-grade glioma (pLGG) that contains a BRAF fusion or rearrangement, or a BRAF V600 mutation.
• The US FDA has accepted and given priority review status to Servier's new drug application for VORASIDENIB, intended for the treatment of IDH-mutant diffuse glioma. The Prescription Drug User Fee Act (PDUFA) action date is scheduled for August 20, 2024.
• In 2023, the total number of incident cases of low-grade glioma in the seven major markets (7MM) exceeded 9,000.
• In 2023, among the seven major markets (7MM), the United States reported the highest number of incident cases of low-grade glioma, with over 3700 cases. These figures are projected to rise during the forecast period.
• Key Low Grade Glioma Companies: Novartis, Day One Biopharmaceuticals, Servier, Nuvation Bio, The Hospital for Sick Children, University of California, Day One Biopharmaceuticals, Daiichi Sankyo Co., Julie Krystal, Novartis, Servier, SpringWorks Therapeutics, AnHeart Therapeutics, Beigene, Helsinn, Forma Therapeutics, Hoffmann-La Roche, and others
• Key Low Grade Glioma Therapies: TAFINLAR (dabrafenib) + MEKINIST (trametinib), OJEMDA (tovorafenib), Vorasidenib, Safusidenib/AB-218, Tovorafenib, Vinblastine, Everolimus, DAY101, DS-1001b, Mebendazole, dabrafenib, Vorasidenib, Mirdametinib, AB-218, BGB-290, Infigratinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, and others
• The Low Grade Glioma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Low Grade Glioma pipeline products will significantly revolutionize the Low Grade Glioma market dynamics.

Low Grade Glioma Overview
Low-grade Gliomas (LGG) constitute a diverse category of primary brain tumors commonly found in younger, otherwise healthy individuals. Typically, these tumors exhibit a relatively slow progression and extended survival rates compared to high-grade gliomas.

Get a Free sample for the Low Grade Glioma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/sample-request/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Low Grade Glioma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Low Grade Glioma Epidemiology Segmentation:
The Low Grade Glioma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Low Grade Glioma
• Prevalent Cases of Low Grade Glioma by severity
• Gender-specific Prevalence of Low Grade Glioma
• Diagnosed Cases of Episodic and Chronic Low Grade Glioma

Download the report to understand which factors are driving Low Grade Glioma epidemiology trends @ Low Grade Glioma Epidemiology Forecast
https://www.delveinsight.com/sample-request/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Low Grade Glioma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Low Grade Glioma market or expected to get launched during the study period. The analysis covers Low Grade Glioma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Low Grade Glioma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Low Grade Glioma Therapies and Key Companies
• TAFINLAR (dabrafenib) + MEKINIST (trametinib): Novartis
• OJEMDA (tovorafenib): Day One Biopharmaceuticals
• Vorasidenib: Servier
• Safusidenib/AB-218: Nuvation Bio
• Tovorafenib: Day One Biopharmaceuticals
• Vinblastine: The Hospital for Sick Children
• Everolimus: University of California
• DAY101: Day One Biopharmaceuticals
• DS-1001b: Daiichi Sankyo Co.
• Mebendazole: Julie Krystal
• dabrafenib: Novartis
• Vorasidenib: Servier
• Mirdametinib: SpringWorks Therapeutics
• AB-218: AnHeart Therapeutics
• BGB-290: Beigene
• Infigratinib: Helsinn
• FT-2102 (Olutasidenib): Forma Therapeutics
• Vinblastine + Bevacizumab: Hoffmann-La Roche, and others

Discover more about therapies set to grab major Low Grade Glioma market share @ Low Grade Glioma Treatment Landscape
https://www.delveinsight.com/sample-request/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Low Grade Glioma Market Strengths
• Low Grade Glioma is a rare form is glioma; thus, companies developing treatment options for the same can possess several advantages like market exclusivities, premium pricing, subsidy for conducting trials, and several other benefits from the government bodies for R&D.

Low Grade Glioma Market Opportunities
• Newer imaging techniques, such as MR spectroscopy (MRS) and positron emission tomography (PET) imaging, may improve the diagnostic potential, challenges exist in the ability for conventional MRI to distinguish between primary tumours versus metastases and CNS masses, and true progression versus pseudo progression.

Scope of the Low Grade Glioma Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Low Grade Glioma Companies: Novartis, Day One Biopharmaceuticals, Servier, Nuvation Bio, The Hospital for Sick Children, University of California, Day One Biopharmaceuticals, Daiichi Sankyo Co., Julie Krystal, Novartis, Servier, SpringWorks Therapeutics, AnHeart Therapeutics, Beigene, Helsinn, Forma Therapeutics, Hoffmann-La Roche, and others
• Key Low Grade Glioma Therapies: TAFINLAR (dabrafenib) + MEKINIST (trametinib), OJEMDA (tovorafenib), Vorasidenib, Safusidenib/AB-218, Tovorafenib, Vinblastine, Everolimus, DAY101, DS-1001b, Mebendazole, dabrafenib, Vorasidenib, Mirdametinib, AB-218, BGB-290, Infigratinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, and others
• Low Grade Glioma Therapeutic Assessment: Low Grade Glioma current marketed and Low Grade Glioma emerging therapies
• Low Grade Glioma Market Dynamics: Low Grade Glioma market drivers and Low Grade Glioma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Low Grade Glioma Unmet Needs, KOL's views, Analyst's views, Low Grade Glioma Market Access and Reimbursement

To know more about Low Grade Glioma companies working in the treatment market, visit @ Low Grade Glioma Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Low Grade Glioma Market Report Introduction
2. Executive Summary for Low Grade Glioma
3. SWOT analysis of Low Grade Glioma
4. Low Grade Glioma Patient Share (%) Overview at a Glance
5. Low Grade Glioma Market Overview at a Glance
6. Low Grade Glioma Disease Background and Overview
7. Low Grade Glioma Epidemiology and Patient Population
8. Country-Specific Patient Population of Low Grade Glioma
9. Low Grade Glioma Current Treatment and Medical Practices
10. Low Grade Glioma Unmet Needs
11. Low Grade Glioma Emerging Therapies
12. Low Grade Glioma Market Outlook
13. Country-Wise Low Grade Glioma Market Analysis (2020-2034)
14. Low Grade Glioma Market Access and Reimbursement of Therapies
15. Low Grade Glioma Market Drivers
16. Low Grade Glioma Market Barriers
17. Low Grade Glioma Appendix
18. Low Grade Glioma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports by DelveInsight

Substance Use Disorder Market
https://www.delveinsight.com/report-store/substance-use-disorder-market
DelveInsight's "Substance Use Disorder Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance Use Disorder, historical and forecasted epidemiology as well as the Substance Use Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Tongue Cancer Market
https://www.delveinsight.com/report-store/tongue-cancer-market
DelveInsight's "Tongue Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Tongue Cancer, historical and forecasted epidemiology as well as the Tongue Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Tumor Ablation Market
https://www.delveinsight.com/report-store/tumor-ablation-market
DelveInsight's 'Tumor Ablation Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Tumor Ablation and the historical and forecasted Tumor Ablation market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Type 2 Diabetes Market
https://www.delveinsight.com/report-store/type-2-diabetes-market
DelveInsight's "Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of Type 2 Diabetes, historical and forecasted epidemiology as well as the Type 2 Diabetes market trends in the United States, EU4 (Germany, Spain, Italy, France), and the United Kingdom, and Japan.

Varicose Vein Market
https://www.delveinsight.com/report-store/varicose-veins-market
DelveInsight's "Varicose Veins Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Varicose Veins, historical and forecasted epidemiology as well as the Varicose Veins market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.